Association of UGT1A1*6 , UGT1A1*28 , or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis-Reference-Cited by-同舟云学术

Association of UGT1A1*6 , UGT1A1*28 , or ABCC2 c.3972C>T genetic polymorphisms with irinotecan‐induced toxicity in Asian cancer patients: Meta‐analysis

Published:2022-05-31 Issue:7 Volume:15 Page:1613-1633
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Atasilp Chalirmporn¹,Biswas Mohitosh²³⁴,Jinda Pimonpan²³,Nuntharadthanaphong Nutthan²³,Rachanakul Jiratha²³,Hongkaew Yaowaluck⁵,Vanwong Natchaya⁶,Saokaew Surasak⁷⁸⁹,Sukasem Chonlaphat²³¹⁰

Affiliation:

1. Chulabhorn International College of Medicine Thammasat University Pathum Thani Thailand

2. Division of Pharmacogenomics and Personalized Medicine, Department of Pathology Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok Thailand

3. Laboratory for Pharmacogenomics, Somdech Phra Debaratana Medical Center (SDMC), Ramathibodi Hospital Bangkok Thailand

4. Department of Pharmacy University of Rajshahi Rajshahi Bangladesh

5. Advance Research and Development Laboratory Bumrungrad International Hospital Bangkok Thailand

6. Department of Clinical Chemistry, Faculty of Allied Health Sciences Chulalongkorn University Bangkok Thailand

7. Division of Pharmacy Practice, Department of Pharmaceutical Care School of Pharmaceutical Sciences, University of Phayao Phayao Thailand

8. Center of Health Outcomes Research and Therapeutic Safety (COHORTS) School of Pharmaceutical Sciences, University of Phayao Phayao Thailand

9. Unit of Excellence on Clinical Outcomes Research and Integration (UNICORN) School of Pharmaceutical Sciences, University of Phayao Phayao Thailand

10. Pharmacogenomics and Precision Medicine, The Preventive Genomics & Family Check‐up Services Center Bumrungrad International Hospital Bangkok Thailand

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13277

Reference80 articles.

1. Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

2. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

3. Bioactivation of the anticancer agent CPT‐11 to SN‐38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions;Slatter JG;Drug Metab Dispos,1997

4. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms;Innocenti F;Oncology (Williston Park),2003

5. Clinical pharmacokinetics and metabolism of irinotecan (CPT‐11);Mathijssen RH;Clin Cancer Res,2001

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functionalized Polymeric Micelles for Targeted Cancer Therapy: Steps from Conceptualization to Clinical Trials;Pharmaceutics;2024-08-06

2. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

3. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study;Clinical Colorectal Cancer;2024-05

4. UGT1A1 genotype‐guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN‐38 concentration;International Journal of Cancer;2023-12-29

5. Effects of Probiotics on Chemotherapy-induced Diarrhea;Nutrition and Cancer;2023-10-31